Normal View Dyslexic View

Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma.

26 April 2023
Randomized clinical trials General
Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR et al.

N Engl J Med 2023; 388: 813-823.

Some 313 patients with advanced melanoma undergoing surgical resection followed by one year of adjuvant Pembrolizumab, were randomly allocated three additional doses of Pembrolizumab preoperatively. After two years, event-free survival was significantly better with the neoadjuvant treatment: 72 versus 49 per cent, P=0.004.

Comment: This is important evidence for the benefit of neoadjuvant treatment for melanoma.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Info
Copied!